Education
About Us
Working with TipRanks
Follow Us
Athira Pharma (ATHA)
NASDAQ:ATHA
ATHA Analyst Ratings
Hold
0 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ATHA Stock 12 Month Forecast
Average Price Target
―| Highest Price Target― | Average Price Target― | Lowest Price Target― |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Citizens JMP
―
Hold
―
Reiterated
05/12/25
Mizuho Securities
―
Hold
―
Reiterated
03/10/25
BTIG
―
Hold
―
Reiterated
03/02/25
Athira Pharma's Strategic Focus on ATH-1105 Amidst Uncertainties: Hold Rating MaintainedWe caught up with management to get additional details about ATH-1105 and the planned study for ALS. Although we haven't seen a lot of data for the FOSGO AD trial, management believes there was enough biomarker support seen to move forward - particularly with a better molecule like ATH-1105. This middling proof of efficacy probably makes sense for ALS where even an established disease-modifying drug like Tofersen, that shows 45% knockdown of the toxic species, could only show proxies for clinical benefit (Nf-L reductions) in a six-month trial. For reference, the target of FOSGO (HGF) always appeared a "likely winner" with reams of supportive pre-clinical data that seemed to create a buzz in the room every time we saw it presented.
Jefferies
$0.5
Hold
61.29%
Upside
Assigned
09/18/24
Lucid Capital
$0.75
Hold
141.94%
Upside
Downgraded
09/04/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Citizens JMP
―
Hold
―
Reiterated
05/12/25
Mizuho Securities
―
Hold
―
Reiterated
03/10/25
BTIG
―
Hold
―
Reiterated
03/02/25
Athira Pharma's Strategic Focus on ATH-1105 Amidst Uncertainties: Hold Rating MaintainedWe caught up with management to get additional details about ATH-1105 and the planned study for ALS. Although we haven't seen a lot of data for the FOSGO AD trial, management believes there was enough biomarker support seen to move forward - particularly with a better molecule like ATH-1105. This middling proof of efficacy probably makes sense for ALS where even an established disease-modifying drug like Tofersen, that shows 45% knockdown of the toxic species, could only show proxies for clinical benefit (Nf-L reductions) in a six-month trial. For reference, the target of FOSGO (HGF) always appeared a "likely winner" with reams of supportive pre-clinical data that seemed to create a buzz in the room every time we saw it presented.
Jefferies
$0.5
Hold
61.29%
Upside
Assigned
09/18/24
Lucid Capital
$0.75
Hold
141.94%
Upside
Downgraded
09/04/24
ATHA Analyst Recommendation Trends
Rating
Sep 24
Nov 24
Feb 25
Mar 25
May 25
Strong Buy
3
3
1
0
0
Buy
2
1
0
0
0
Hold
8
9
10
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
13
11
3
3
Each month's total comprises the sum of three months' worth of ratings.
ATHA Financial Forecast
ATHA Stock Forecast FAQ
What is ATHA’s average 12-month price target, according to analysts?
Currently, no data Available
What is ATHA’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for ATHA, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ATHA a Buy, Sell or Hold?
Athira Pharma has a consensus rating of Hold which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.
What is Athira Pharma’s price target?
Currently, no data Available
What do analysts say about Athira Pharma?
Athira Pharma’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.
How can I buy shares of ATHA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.